Idera Pharmaceuticals is focused on applying its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The company has a clinical development program in autoimmune diseases as well as a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. Idera is exploring its gene-silencing oligonucleotide technology for inhibiting the expression of disease-promoting genes. For more information, visit the company’s Web site at www.iderapharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: